The functional expression of ΔF508 and various other CF variants can be partially restored by Trikafta, an FDA-approved cocktail of two correctors that stabilize the CFTR protein (VX-661 + VX-445) and a potentiator that activates it (VX-770).28–30 To determine whether ribosomal frameshifting potentially influences the effects of these compounds, we assessed whether the RF motif impacts the pharmacological rescue of ΔF508 CFTR. The gene discussed is CFTR; the disease is cystic fibrosis.